Literature DB >> 15745986

Risks and benefits of phase 1 oncology trials, revisited.

Razelle Kurzrock, Robert S Benjamin.   

Abstract

Keywords:  Biomedical and Behavioral Research

Mesh：

Substances：

Year:  2005        PMID： 15745986     DOI： 10.1056/NEJMe058007

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  29 in total

1.  Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Authors:  Denis L Jardim; Denis L Fontes Jardim; Maria Schwaederle; Caimiao Wei; J Jack Lee; David S Hong; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Natl Cancer Inst       Date:  2015-09-15       Impact factor: 13.506

2.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

Authors:  Filip Janku; Jennifer J Wheler; Shannon N Westin; Stacy L Moulder; Aung Naing; Apostolia M Tsimberidou; Siqing Fu; Gerald S Falchook; David S Hong; Ignacio Garrido-Laguna; Rajyalakshmi Luthra; J Jack Lee; Karen H Lu; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

3.  Prognostic factors among cancer patients with good performance status screened for phase I trials.

Authors:  Nicolas Penel; Marie Vanseymortier; Marie-Edith Bonneterre; Stéphanie Clisant; Eric Dansin; Yvette Vendel; Régis Beuscart; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2007-09-22       Impact factor: 3.850

4.  Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience.

Authors:  John Moroney; Jennifer Wheler; David Hong; Aung Naing; Gerald Falchook; Diane Bodurka; Robert Coleman; Karen Lu; Lianchun Xiao; Razelle Kurzrock
Journal:  Gynecol Oncol       Date:  2010-03-26       Impact factor: 5.482

5.  Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.

Authors:  Prasanth Ganesan; Stacy Moulder; J Jack Lee; Filip Janku; Vicente Valero; Ralph G Zinner; Aung Naing; Siqing Fu; Apostolia M Tsimberidou; David Hong; Bettzy Stephen; Philip Stephens; Roman Yelensky; Funda Meric-Bernstam; Razelle Kurzrock; Jennifer J Wheler
Journal:  Mol Cancer Ther       Date:  2014-09-24       Impact factor: 6.261

6.  Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors:  S Percy Ivy; Lillian L Siu; Elizabeth Garrett-Mayer; Larry Rubinstein
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

7.  Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.

Authors:  Robert J Canter; Dariusz Borys; Abimbola Olusanya; Chin-Shang Li; Li-Yuan Lee; Robert D Boutin; Scott D Christensen; Robert M Tamurian; Arta M Monjazeb
Journal:  Ann Surg Oncol       Date:  2014-02-20       Impact factor: 5.344

8.  Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.

Authors:  Prasanth Ganesan; Filip Janku; Aung Naing; David S Hong; Apostolia M Tsimberidou; Gerald S Falchook; Jennifer J Wheler; Sarina A Piha-Paul; Siqing Fu; Vanda M Stepanek; J Jack Lee; Rajyalakshmi Luthra; Michael J Overman; E Scott Kopetz; Robert A Wolff; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2013-10-03       Impact factor: 6.261

Review 9.  Compliance in early-phase cancer clinical trials research.

Authors:  Razelle Kurzrock; David J Stewart
Journal:  Oncologist       Date:  2013-03-01

10.  Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.

Authors:  Filipa Lynce; Matthew J Blackburn; Ling Cai; Heping Wang; Larry Rubinstein; Pamela Harris; Claudine Isaacs; Paula R Pohlmann
Journal:  Breast Cancer Res Treat       Date:  2017-11-08       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.